Werewolf Therapeutics, Inc. Operating Income Loss

• Werewolf Therapeutics, Inc. showed an increase of +17.6% in Operating Income Loss from 2024 to 2025.
• This data is from Werewolf Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2020 to 2025), Werewolf Therapeutics, Inc.'s Operating Income Loss has declined by 170.8%.
• Historical annual values: Fiscal year 2025: -$60.68 million | Fiscal year 2024: -$73.59 million | Fiscal year 2023: -$40.50 million | Fiscal year 2022: -$56.06 million | Fiscal year 2021: -$50.09 million | Fiscal year 2020: -$22.40 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026